A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Administered By
Awarded By
Contributors
- George, Daniel James Principal Investigator
Start/End
- April 2, 2019 - April 20, 2024